Resection of metastases in patients with BRAF mutated metastatic colon cancer: results of a multicenter retrospective study

Introduction: local treatment of metastases is an integral part of colon cancer treatment. However, there is not enough data on the efficacy of surgical resection of metastases in patients with a BRAF gene mutation to recom‑mend this approach in routine practice. We initiated a retrospective multicenter study to assess the incidence of BRAF gene mutations in patients with metastatic colon cancer and to study the efficacy of metastasectomy in this group of patients.

Materials and methods: we selected all patients who underwent surgical resection of metastases in various sites from the database of patients with BRAF gene mutations created as a result of a multicenter retrospective study with participation of 7 clinics in the Russian Federation. All 57 patients with RAS gene mutations and 43 patients with wild‑type RAS and BRAF genes who also underwent surgical resection of metastases at any stage of treatment were selected from the register of the Chemotherapy Department No. 2 of the NMRC of Oncology named after N. N. Blokhin for comparative analysis. Disease‑free survival and overall survival were used as primary efficacy criteria.

Results: we found 26 patients with BRAF gene mutations who underwent surgical resection of metastases. When comparing disease‑free survival, the worst median was achieved in the group of patients with BRAF gene mutations: 7 months versus 14 months in patients with RAS gene mutations (HR 0.4, 94 % CI 0.23–0.7, P = 0.006); median disease‑free survival was not achieved in the wild‑type RAS and BRAF group (HR 0.2, 95 % CI 0.11–0.45, P <0.001).

The median overall survival in the BRAF gene mutation group was 26 months versus 38 months in the RAS gene mutations group (HR 0.8, 95 % CI 0.33–1.98, P = 0.6) and 49 months in the wtRAS/wtBRAF group (RR 0.46, 95 % CI 0.17–1.24, P = 0.1). Resection of recurrent tumors in patients with metastases in retroperitoneal lymph nodes was associated with extremely low disease‑free survival (2 months); at the same time, disease‑free survival was 7 months after resection of isolated metastases in the liver and 8 months for metastases in the peritoneum.

Conclusion: prognosis of patients with a BRAF gene mutation after surgical resection of metastases is worse than in patients with a different mutation phenotype. Nevertheless, literature data, as well as the results of our study, confirm the possibility of performing metastasectomy with careful selection of patients.

1. Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer. 2018; 18: 78.

2. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1;27 (22):3677-83. doi: 10.1200/JCO. 2008.20.5278.

3. Adam R, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, Capussotti L, Lapointe R, Regimbeau JM, Lopez – Ben

4. S, Isoniemi H, Hubert C, Lin JK, Gruenberger T, Elias D, Skipenko OG, Guglielmi A, LiverMetSurvey International Contributing Centers. Resection of colorectal liver metastases afer second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer. 2017 Jun;78:7-15. doi: 10.1016/j. ejca. 2017.03.009.

5. Spolverato G, Ejaz A, Azad N and Pawlik TM. Surgery for colorectal liver metastases: Te evolution of determining prognosis. World J Gastrointest Oncol. 2013 Dec 15; 5 (12): 207–221. doi: 10.4251/wjgo.v5.i12.207.

6. Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jäger D, Büchler MW, Weitz J, Koch M. Adjuvant therapy afer resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer. 2014;14:174. DOI: https://doi.org/10.1186/1471-2407-14-174.

7. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009 Sep;250 (3):440-8. doi: 10.1097/SLA. 0b013e3181b4539b.

8. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal L F, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of fve randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol. 2016 Sep;27 (9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.

9. Chu JE, Johnson B, Morris VK, Raghav KPS, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Schaeffer DF, Kopetz S, Loree JM. Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis. Journal of Clinical Oncology. 2019;37, no. 15_suppl: 3579-3579. DOI: 10.1200/JCO. 2019.37.15_suppl. 3579.

10. Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Taler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, Laurent-Puig P, Pan-European Trials in Alimentary Tract Cancer (PETACC) -8 Investigators. Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status. JAMA Oncol. 2018 Jul 12;4 (7):e173695. doi: 10.1001/jamaoncol. 2017.3695.

11. Renaud S, Romain B, Falcoz P-E, Olland A, Santelmo N, Brigand C, Rohr S, Guenot D, Massard G. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. Br J Cancer. 2015 Feb 17;112 (4):720-8. doi: 10.1038/bjc. 2014.499.

12. Hernández-Sandoval JA, Gutiérrez-Angulo M, Magaña-Torres MT, Alvizo-Rodríguez CR, Ramírez-Plascencia HHF, Flores-López BA, Valenzuela-Pérez JA, Peregrina-Sandoval J, Moreno-Ortiz JM, Domínguez-Valentín M, de la Luz Ayala-Madrigal M. Prevalence of the BRAF p. v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. J Investig Med. 2020 Jun;68 (5):985-991. doi: 10.1136/jim-2020-001301. Oncol Rep. https://doi.org/10.3892/or.2011.1217.

13. Morris VK, Kee BK, Overman MJ, Fogelman DR, Dasari A, Raghav KPS, Shureiqi I, Johnson B, Parseghian CM, Wolff RA, Eng C, Garg N, Kopetz S. Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. J Clin Oncol 38: 2020 (suppl; abstr 4047). DOI: 10.1200/JCO.2020.38.15_suppl.4047.

14. Ortega L, Beranek MB, Alonso NG, Alsar JS, Bianchi MA, Valles MA, Salcedo IA, Gallego IG, González GG, Pérez-Solero GT, Martín AJM, Ferrándiz AC, Blanco-Codesido M, Martin M, Garcia-Alfonso P. Metastases resection in colorectal cancer patients with mutation in oncogene BRAF or tumors located on the right side: Experience at the HGUGM. J Clin Oncol 38: 2020 (suppl; abstr 4041). DOI: 10.1200/JCO. 020.38.15_suppl.4041.

15. Prasanna T, Wong R, Price T, Shapiro J, Tie J, Wong HL, Nott L, Roder D, Lee M, Kosmider S, Jalali A, Burge M, Padbury R, Maddern G, Carruthers S, Moore J, Sorich M, Karapetis CS, Gibbs P, Yip D. Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Curr Probl Cancer. 2020 Aug 14;100637. doi: 10.1016/j. currproblcancer. 2020.100637. Online ahead of print.

16. Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg. 2018 Jul 18;153 (7):e180996. doi: 10.1001/jamasurg. 2018.0996.

17. Johnson B, Jin Z, Truty MJ, et al. Impact of metastasectomy in the multimodality approach for braf v600e metastatic colorectal cancer: the Mayo Clinic experience. Oncologist. 2018;23:128–134. doi:10.1634/theoncologist. 2017-0230.

18. Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015;112:1921–1928. doi:10.1038/bjc. 2015.142.

19. Teng HW, Huang YC, Lin JK et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 2012;106:123–129.

20. Yaeger R, Cercek A, Chou JF et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014;120:2316–2324.

21. Larsen SG, Dueland S, Goscinski M, et al. Survival according to mutations in BRAF, KRAS, or microsatellite instability (MSI-H) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peri-toneal metastases from colorectal cancer. J Clin Oncol. 2019;37 (15_suppl): 3565. doi:10.1200/JCO. 2019.37.15_suppl.3565.

22. Montañá JR, Martini G, Baraibar I, Villacampa G, Comas R, Ciardiello D, Garcia A, Yague XH, Queralt B, Salvia AS, Argiles G, Cuadra JL, Toledo RA, Chicote I, Mulet N, Vivancos A, Palmer HG, Dienstmann R, Tabernero J, Elez E. Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) meta-static colorectal cancer (mCRC) treated with doublet or triplet targeted therapy. J Clin Oncol 38: 2020 (suppl; abstr 4112). DOI: 10.1200/JCO.2020.38.15_suppl.4112.

23. Montañá JR, Martini G, Baraibar I, Villacampa G, Comas R, Ciardiello D, Garcia A, Yague XH, Queralt B, Salvia AS, Argiles G, Cuadra JL, Toledo RA, Chicote I, Mulet N, Vivancos A, Palmer HG, Dienstmann R, Tabernero J, Elez E. Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) meta-static colorectal cancer (mCRC) treated with doublet or triplet targeted therapy. J Clin Oncol 38: 2020 (suppl; abstr 4112). DOI: 10.1200/JCO.2020.38.15_suppl.4112.